What is StageZero Life Sciences Price-to-Operating-Cash-Flow?
As of today (2024-04-30), StageZero Life Sciences's share price is C$0.04.
StageZero Life Sciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 was C$-0.01. Hence, StageZero Life Sciences's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for StageZero Life Sciences's Price-to-Operating-Cash-Flow or its related term are showing as below:
StageZero Life Sciences's Cash Flow from Operations per share for the
three
months ended in Sep. 2023 was C$0.00.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 was C$-0.01.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 35.40% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 30.90% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 25.00% per year.
During the past 13 years, StageZero Life Sciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 41.40% per year. The lowest was -247.50% per year. And the median was 17.80% per year.
StageZero Life Sciences Price-to-Operating-Cash-Flow Historical Data
The historical data trend for StageZero Life Sciences's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StageZero Life Sciences Price-to-Operating-Cash-Flow Chart
|
StageZero Life Sciences Annual Data
|
|
Trend |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
StageZero Life Sciences Quarterly Data
|
|
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of StageZero Life Sciences's Price-to-Operating-Cash-Flow
For the Diagnostics & Research subindustry, StageZero Life Sciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StageZero Life Sciences's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where StageZero Life Sciences's Price-to-Operating-Cash-Flow falls into.
StageZero Life Sciences Price-to-Operating-Cash-Flow Calculation
StageZero Life Sciences's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 0.04 | / | -0.011 |
| = | |
StageZero Life Sciences's Share Price of today is C$0.04.
StageZero Life Sciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
StageZero Life Sciences (TSX:SZLS) Business Description
Traded in Other Exchanges
Address
70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
StageZero Life Sciences (TSX:SZLS) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSX:SZLS has been successfully added to your